Related references
Note: Only part of the references are listed.Antibodies to watch in 2017
Janice M. Reichert
MABS (2017)
Gene Editing Regulatory and Translation to Clinic
Dale Ando et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2017)
Structure of CC Chemokine Receptor 5 with a Potent Chemokine Antagonist RevealsMechanisms of Chemokine Recognition and Molecular Mimicry by HIV
Yi Zheng et al.
IMMUNITY (2017)
The possible role of CCR5Δ32 mutation in Crimean-Congo hemorrhagic fever infection
Aydin Rustemoglu et al.
JOURNAL OF MEDICAL VIROLOGY (2017)
Refining strategies to translate genome editing to the clinic
Tatjana I. Cornu et al.
NATURE MEDICINE (2017)
Opportunities for therapeutic antibodies directed at G-protein-coupled receptors
Catherine J. Hutchings et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
The recipient CCR5 variation predicts survival outcomes after bone marrow transplantation
Tomohiro Horio et al.
TRANSPLANT IMMUNOLOGY (2017)
The Role of Natural Antibodies to CC Chemokine Receptor 5 in HIV infection
Assunta Venuti et al.
FRONTIERS IN IMMUNOLOGY (2017)
Early involvement of cellular stress and inflammatory signals in the pathogenesis of tubulointerstitial kidney disease due to UMOD mutations
Matteo Trudu et al.
SCIENTIFIC REPORTS (2017)
CCR5-edited gene therapies for HIV cure: Closing the door to viral entry
Kevin G. Haworth et al.
CYTOTHERAPY (2017)
Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis
Ryan H. Moy et al.
BLOOD (2017)
Recent advances in RNAi-based strategies for therapy and prevention of HIV-1/AIDS
Manjunath N. Swamy et al.
ADVANCED DRUG DELIVERY REVIEWS (2016)
Interfering with CCL5/CCR5 at the Tumor-Stroma Interface
Vincenzo Bronte et al.
CANCER CELL (2016)
CCR5+T-bet+FoxP3+ Effector CD4 T Cells Drive Atherosclerosis
Jie Li et al.
CIRCULATION RESEARCH (2016)
Maraviroc contributes to the restoration of the homeostasis of regulatory T-cell subsets in antiretroviral-naive HIV-infected subjects
M. M. Pozo-Balado et al.
CLINICAL MICROBIOLOGY AND INFECTION (2016)
Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design
Scott Friedman et al.
CONTEMPORARY CLINICAL TRIALS (2016)
Staphylococcus aureus Leukocidin LukED and HIV-1 gp120 Target Different Sequence Determinants on CCR5
Kayan Tam et al.
MBIO (2016)
Highly specific blockade of CCR5 inhibits leukocyte trafficking and reduces mucosal inflammation in murine colitis
Andrea Mencarelli et al.
Scientific Reports (2016)
I Am the Berlin Patient: A Personal Reflection
Timothy Ray Brown
AIDS RESEARCH AND HUMAN RETROVIRUSES (2015)
Dengue virus requires the CC-chemokine receptor CCR5 for replication and infection development
Rafael E. Marques et al.
IMMUNOLOGY (2015)
Elevated chemokine levels during adult but not pediatric Crimean-Congo hemorrhagic fever
Mehmet Arasli et al.
JOURNAL OF CLINICAL VIROLOGY (2015)
CCR5 Targeted Cell Therapy for HIV and Prevention of Viral Escape
Gero Huetter et al.
VIRUSES-BASEL (2015)
Maraviroc: a review of its use in HIV infection and beyond
Shawna M. Woollard et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2015)
A Linear Epitope in the N-Terminal Domain of CCR5 and Its Interaction with Antibody
Benny Chain et al.
PLOS ONE (2015)
CC Chemokine Receptor 5: The Interface of Host Immunity and Cancer
Carlos Eduardo Coral de Oliveira et al.
DISEASE MARKERS (2014)
The potential to target CCL5/CCR5 in breast cancer
Marco Velasco-Velazquez et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2014)
The Inflammatory Chemokine CCL5 and Cancer Progression
Donatella Aldinucci et al.
MEDIATORS OF INFLAMMATION (2014)
CCR5 Controls Immune and Metabolic Functions during Toxoplasma gondii Infection
Giuliano Bonfa et al.
PLOS ONE (2014)
Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases
Michela Flego et al.
BMC MEDICINE (2013)
In vitro effects of the CCR5 inhibitor maraviroc on human T cell function
H. Arberas et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
CCR5 is a receptor for Staphylococcus aureus leukotoxin ED
Francis Alonzo et al.
NATURE (2013)
Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial
Stefano Rusconi et al.
PLOS ONE (2013)
Structure of the CCR5 Chemokine Receptor-HIV Entry Inhibitor Maraviroc Complex
Qiuxiang Tan et al.
SCIENCE (2013)
C-C chemokine receptor type five (CCR5): An emerging target for the control of HIV infection
Fatima Barmania et al.
APPLIED AND TRANSLATIONAL GENOMICS (2013)
CCR5 as a Potential Target in Cancer Therapy: Inhibition or Stimulation?
Alicia Gonzalez-Martin et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2012)
Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial
Dona L. Fleishaker et al.
ARTHRITIS RESEARCH & THERAPY (2012)
Chemokine receptor CCR5: from AIDS to atherosclerosis
K. L. Jones et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Resistance to the CCR5 Inhibitor 5P12-RANTES Requires a Difficult Evolution from CCR5 to CXCR4 Coreceptor Use
Rebecca Nedellec et al.
PLOS ONE (2011)
Engineering of Lactobacillus jensenii To Secrete RANTES and a CCR5 Antagonist Analogue as Live HIV-1 Blockers
Luca Vangelista et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
CCL5 as an adjuvant for cancer immunotherapy
Natalia Lapteva et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2010)
Expression of Chemokines and Their Receptors by Human Brain Endothelium: Implications for Multiple Sclerosis
Eve A. Subileau et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2009)
Role for CCR5 in Dissemination of Vaccinia Virus In Vivo
Ramtin Rahbar et al.
JOURNAL OF VIROLOGY (2009)
OPINION Chemokine receptor antagonists: overcoming developmental hurdles
Richard Horuk
NATURE REVIEWS DRUG DISCOVERY (2009)
Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantaion
Gero Huetter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Safety concerns about CCR5 as an antiviral target
Amalio Telenti
CURRENT OPINION IN HIV AND AIDS (2009)
Chemotaxis, chemokine receptors and human disease
Tian Jin et al.
CYTOKINE (2008)
A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis
Elin Kindberg et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile Virus infection: A meta-analysis of 4 cohorts in the US epidemic
Jean K. Lim et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases
Elena E. Perez et al.
NATURE BIOTECHNOLOGY (2008)
Subgroup analyses of Maraviroc in previously treated R5 HIV-1 infection
Gerd Faetkenheuer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Highly potent, fully recombinant anti-HIV chemokines: Reengineering a low-cost microbicide
Hubert Gaertner et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Rational design of novel HIV-1 entry inhibitors by RANTES engineering
Luca Vangelista et al.
VACCINE (2008)
Hepatotoxicity observed in clinical trials of aplaviroc (GW873140)
W. G. Nichols et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
CCL5 and CCR5 genotypes modify clinical, radiological and pathological features of multiple sclerosis
Tineke van Veen et al.
JOURNAL OF NEUROIMMUNOLOGY (2007)
Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment experienced patients: AIDS clinical trials group 5211
Roy M. Gulick et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
Novel CCR5 monoclonal antibodies with potent and broad-spectrum anti-HIV activities
Changhua Ji et al.
ANTIVIRAL RESEARCH (2007)
CCR5: no longer a 'good for nothing' gene - chemokine control of West Nile virus infection
Jean K. Lim et al.
TRENDS IN IMMUNOLOGY (2006)
'Ground truth' for selection on CCR5-Δ32
Philip W. Hedrick et al.
TRENDS IN GENETICS (2006)
Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: Synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety
M Seto et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
HIV and the chemokine system: 10 years later
P Lusso
EMBO JOURNAL (2006)
CCR5Δ32 polymorphism effects on CCR5 expression, patterns of immunopathology and disease course in multiple sclerosis
OH Kantarci et al.
JOURNAL OF NEUROIMMUNOLOGY (2005)
Detection of the CCR5-Δ32 HIV resistance gene in Bronze Age skeletons
S Hummel et al.
GENES AND IMMUNITY (2005)
Evidence for negative association of the chemokine receptor CCR5 d32 polymorphism with rheumatoid arthritis
V Pokorny et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
The cerebral-malaria-associated expression of RANTES, CCR3 and CCR5 in post-mortem tissue samples
BY Sarto et al.
ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY (2004)
Piperazine-based CCR5 antagonists as HIV-1 inhibitors.: IV.: Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-4-[4-{2-methoxy-1(R)-4-(trifluoromethyl)-phenyl}ethyl-3(S)-methyl-1-piperazinyl]-4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist
JR Tagat et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Influence of CCR5 delta 32 polymorphism on multiple sclerosis susceptibility and disease course
JA Silversides et al.
MULTIPLE SCLEROSIS JOURNAL (2004)
Drug discovery with engineered zinc-finger proteins
AC Jamieson et al.
NATURE REVIEWS DRUG DISCOVERY (2003)
Molecular mimicry of a CCR5 binding-domain in the microbial activation of dendritic cells
J Alberti et al.
NATURE IMMUNOLOGY (2003)
Piperazine-based CCR5 antagonists as HIV-1 inhibitors. III: Synthesis, antiviral and Pharmacokinetic profiles of symmetrical Heteroaryl Carboxamides
SW McCombie et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2003)
Tissue cytokine and chemokine expression in inflammatory bowel disease
G McCormack et al.
INFLAMMATION RESEARCH (2001)
CXCR3 and CCR5 ligands in rheumatoid arthritis synovium
DD Patel et al.
CLINICAL IMMUNOLOGY (2001)
Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140
A Trkola et al.
JOURNAL OF VIROLOGY (2001)
Macrophage inflammatory protein-1α (MIP-1α), MIP-1β, and RANTES mRNA semiquantification and protein expression in active demyelinating multiple sclerosis (MS) lesions
LA Boven et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2000)
Expression of the β-chemokines RANTES and MIP-1β by human brain microvessel endothelial cells in primary culture
JA Shukaliak et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2000)
Share Paper
